Literature DB >> 29120858

Prognostic value of fibrosis-related markers in dilated cardiomyopathy: A link between osteopontin and cardiovascular events.

Paweł Rubiś1, Sylwia Wiśniowska-Śmiałek2, Ewa Dziewięcka2, Lucyna Rudnicka-Sosin3, Artur Kozanecki2, Piotr Podolec4.   

Abstract

INTRODUCTION: Serum markers of fibrosis provide an insight into extracellular matrix (ECM) fibrosis in heart failure (HF) and dilated cardiomyopathy (DCM). However, their role as predictors of cardiovascular (CV) events in DCM is poorly understood.
METHODS: This is an observational, prospective cohort study. 70 DCM patients (48±12.1years, ejection fraction - EF 24.4±7.4) were recruited. Markers of collagen type I and III synthesis - procollagen type I and III carboxy- and amino-terminal peptides (PICP, PIIICP, PINP, PIIINP), fibrosis controlling factors - ostepontin (OPN), transforming growth factor (TGF1-β) and connective tissue growth factor (CTGF), and matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitor (TIMP-1), were measured in serum. All patients underwent endomyocardial biopsy. The end-point was combined with CV death and urgent HF hospitalization. Patients were divided into two groups: those who did (group 1, n=45) and did not reach (group 2, n=25) an end-point.
RESULTS: Over a 12-month period of observation, 6 CV deaths and 19 HF hospitalizations occurred. Qualitative and quantitative measures of ECM fibrosis were similar in both groups. The levels of all of the markers of collagen synthesis, TGF1-β, MMP-9 and TIMP-1 were similar, however, OPN, CTGF and MMP-2 were significantly lower in group 1.
CONCLUSIONS: Invasively-determined fibrosis levels were not related with CV outcomes in DCM. Out of the 11 markers of fibrosis under study, only OPN was found to be related to CV outcomes. OPN is not only the pivotal protein controlling fibrosis, but may also serve as a biomarker associated with prognosis.
Copyright © 2017 Medical University of Bialystok. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biopsy; Dilated cardiomyopathy; Fibrosis; Follow-up; Markers; Osteopontin

Mesh:

Substances:

Year:  2017        PMID: 29120858     DOI: 10.1016/j.advms.2017.10.004

Source DB:  PubMed          Journal:  Adv Med Sci        ISSN: 1896-1126            Impact factor:   3.287


  9 in total

Review 1.  Regulation and bioactivity of the CCN family of genes and proteins in obesity and diabetes.

Authors:  Stephen M Twigg
Journal:  J Cell Commun Signal       Date:  2018-02-06       Impact factor: 5.782

Review 2.  Role of cytokines and inflammation in heart function during health and disease.

Authors:  Monika Bartekova; Jana Radosinska; Marek Jelemensky; Naranjan S Dhalla
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

3.  ERK1/2 communicates GPCR and EGFR signaling pathways to promote CTGF-mediated hypertrophic cardiomyopathy upon Ang-II stimulation.

Authors:  Xin Liu; Lin Lin; Qing Li; Yajuan Ni; Chaoying Zhang; Shuguang Qin; Jin Wei
Journal:  BMC Mol Cell Biol       Date:  2019-06-14

Review 4.  Osteopontin: A Promising Therapeutic Target in Cardiac Fibrosis.

Authors:  Iman Abdelaziz Mohamed; Alain-Pierre Gadeau; Anwarul Hasan; Nabeel Abdulrahman; Fatima Mraiche
Journal:  Cells       Date:  2019-12-03       Impact factor: 6.600

5.  Diminished PLK2 Induces Cardiac Fibrosis and Promotes Atrial Fibrillation.

Authors:  Stephan R Künzel; Maximilian Hoffmann; Michael Wagner; Ali El-Armouche; Silvio Weber; Karolina Künzel; Susanne Kämmerer; Mario Günscht; Erik Klapproth; Johanna S E Rausch; Mirna S Sadek; Tomasz Kolanowski; Stefanie Meyer-Roxlau; Christopher Piorkowski; Sems M Tugtekin; Stefan Rose-John; Xiaoke Yin; Manuel Mayr; Jan Dominik Kuhlmann; Pauline Wimberger; Konrad Grützmann; Natalie Herzog; Jan-Heiner Küpper; Molly O'Reilly; S Nashitha Kabir; Laura C Sommerfeld; Kaomei Guan; Ben Wielockx; Larissa Fabritz; Stanley Nattel; Ursula Ravens; Dobromir Dobrev
Journal:  Circ Res       Date:  2021-08-26       Impact factor: 17.367

Review 6.  Clinical and Molecular Implications of Osteopontin in Heart Failure.

Authors:  Argen Mamazhakypov; Meerim Sartmyrzaeva; Akpay Sh Sarybaev; Ralph Schermuly; Akylbek Sydykov
Journal:  Curr Issues Mol Biol       Date:  2022-08-11       Impact factor: 2.976

7.  Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin.

Authors:  Kate M Herum; Andreas Romaine; Ariel Wang; Arne Olav Melleby; Mari E Strand; Julian Pacheco; Bjørn Braathen; Pontus Dunér; Theis Tønnessen; Ida G Lunde; Ivar Sjaastad; Cord Brakebusch; Andrew D McCulloch; Maria F Gomez; Cathrine R Carlson; Geir Christensen
Journal:  J Am Heart Assoc       Date:  2020-01-31       Impact factor: 5.501

8.  Enhanced osteopontin splicing regulated by RUNX2 is HDAC-dependent and induces invasive phenotypes in NSCLC cells.

Authors:  Jing Huang; Siyuan Chang; Yabin Lu; Jing Wang; Yang Si; Lijian Zhang; Shan Cheng; Wen G Jiang
Journal:  Cancer Cell Int       Date:  2019-11-21       Impact factor: 5.722

Review 9.  Osteopontin: The Molecular Bridge between Fat and Cardiac-Renal Disorders.

Authors:  Elena Vianello; Marta Kalousová; Elena Dozio; Lorenza Tacchini; Tomáš Zima; Massimiliano Marco Corsi Romanelli
Journal:  Int J Mol Sci       Date:  2020-08-04       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.